SCENESSE ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
159	色素性乾皮症	4
161	家族性良性慢性天疱瘡	1
254	ポルフィリン症	2

159. 色素性乾皮症

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-001419-10-ES (EUCTR)	31/01/2022	17/11/2021	Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotide in patients ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: SCENESSE Product Name: Afamelanotide (16 mg implant)	CLINUVEL EUROPE LIMITED	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	6	Phase 2	Belgium;Spain
2	EUCTR2021-003642-20-DE (EUCTR)	27/09/2021	09/07/2021	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: Afamelanotide	CLINUVEL EUROPE LTD	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	6	Phase 2	Germany
3	EUCTR2019-000597-34-DE (EUCTR)	01/06/2021	11/01/2021	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous I ...	xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases ...	Trade Name: SCENESSE Product Name: SCENESSE INN or Proposed INN: AFAMELANOTIDE	CLINUVEL EUROPE LIMITED	NULL	Not Recruiting	Female: yes Male: yes	6	Phase 2	Germany
4	EUCTR2021-001419-10-BE (EUCTR)		16/11/2021	Study to evaluate the safety and efficacy of the photoprotective drug, afamelanotide in patients wit ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous ...	Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, ...	Trade Name: SCENESSE Product Name: Afamelanotide (16 mg implant)	CLINUVEL EUROPE LIMITED	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	6	Phase 2	Spain;Belgium

First Previous1Next Last

161. 家族性良性慢性天疱瘡

臨床試験数 : 5 / 薬物数 : 9 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 24

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-004562-33-IT (EUCTR)	17/12/2013	18/11/2013	PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELA ...	PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELA ...	SYMPTOMATIC HHD PATIENTS MedDRA version: 16.1;Level: LLT;Classification code 10019029;Term: Hailey-H ...	Trade Name: SCENESSE Product Name: SCENESSE	ISTITUTI FISIOTERAPICI OSPITALIERI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	10	Phase 2	Italy

First Previous1Next Last

254. ポルフィリン症

臨床試験数 : 72 / 薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004164-60-NL (EUCTR)	19/05/2022	21/02/2022	Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP) ...	A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide ...	Variegate Porphyria (VP)-related skin disease;Therapeutic area: Body processes [G] - Metabolic Pheno ...	Trade Name: SCENESSE	CLINUVEL (UK) LTD	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	6	Phase 2	Netherlands;Switzerland
2	EUCTR2009-011018-51-GB (EUCTR)	15/06/2009	27/04/2009	A Phase III, Safety Extension Study in Patients withErythropoietic Protoporphyria (EPP) - Phase III ...	A Phase III, Safety Extension Study in Patients withErythropoietic Protoporphyria (EPP) - Phase III ...	Erythropoietic Protoporphyria (EPP) MedDRA version: 13.1;Level: LLT;Classification code 10015289;Ter ...	Product Name: Afamelanotide Product Code: CUV1647 INN or Proposed INN: afamelanotide Other descriptive ...	Clinuvel Pharmaceuticals Limited	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 3	Finland;United Kingdom;Netherlands;Ireland

First Previous1Next Last

先頭へ